Peerbridge Health Company Profile

Background

Peerbridge Health is a digital health company dedicated to transforming remote healthcare through advanced AI-driven electrocardiogram (ECG) platforms. Founded by Dr. Angelo Acquista, a New York City-based pulmonologist, the company was inspired by the need for more patient-friendly cardiac monitoring solutions. Its mission is to provide innovative, wearable ECG technology that enables faster, more accurate, and affordable diagnoses, thereby enhancing patients' quality of life. Peerbridge Health's primary focus is on developing and deploying remote diagnostic platforms that leverage ECG data to predict and diagnose prevalent chronic illnesses, such as heart failure, atrial fibrillation, and obstructive sleep apnea.

Key Strategic Focus

The company's strategic objectives center on advancing remote patient diagnostics through AI-enabled ECG technology. Its specialization lies in creating wearable ambulatory ECG (AECG) devices that combine superior recording fidelity with proprietary algorithms. Key technologies include the Peerbridge Cor™, a patented 3-lead, 2-channel wireless AECG patch designed based on Einthoven's Triangle, which mirrors traditional 12-lead Holter placement. This technology targets primary markets such as cardiology practices, hospitals, and home healthcare settings, aiming to address conditions like heart failure, atrial fibrillation, and sleep apnea.

Financials and Funding

Peerbridge Health has successfully secured significant funding to support its growth and innovation initiatives. In March 2023, the company raised $10 million in a funding round led by Mendota Venture Capital and HealthX Ventures. This capital is intended to accelerate the development and deployment of Peerbridge Health's AI-driven remote diagnostic platform. Additionally, in 2019, the company secured $11 million in funding from investors including Northwell Health, Ascent Biomedical Ventures, and its founder, Dr. Angelo Acquista. These funds have been utilized to enhance product development, expand market reach, and support clinical trials.

Pipeline Development

Peerbridge Health has been actively involved in clinical trials to validate its technologies:

EF-ACT Pivotal Trial: Initiated to determine Left Ventricular Ejection Fraction (LVEF) severity using the AI-enabled Peerbridge Cor™ wearable.

COR-INSIGHT Trial: Launched in January 2025, this trial aims to validate the screening and diagnostic capabilities of the Peerbridge Cor® ambulatory ECG wearables across over 30 cardiac and cardiopulmonary indications. The trial plans to enroll up to 15,000 participants from diverse demographics.

Technological Platform and Innovation

Peerbridge Health's innovation is anchored in its proprietary technologies and scientific methodologies:

Peerbridge Cor™: A patented 3-lead, 2-channel wireless AECG patch designed based on Einthoven's Triangle, providing superior recording fidelity, P-wave definition, and QRS morphology.

AI-Driven Algorithms: The company employs advanced AI algorithms to analyze ECG data, enabling early detection and diagnosis of chronic conditions such as heart failure and sleep apnea.

CardioMIND and CardioQSync Platforms: These proprietary AI Software as a Medical Device (SaMD) platforms are utilized for cardiovascular indications and sleep disorder analysis, as well as for extracting cardiopulmonary and hemodynamic indications from respiratory ECG.

Leadership Team

The leadership team at Peerbridge Health comprises experienced professionals:

Chris Darland, CEO and President: Appointed in 2023, Darland brings over 15 years of global finance and operating experience across multiple industries, including healthcare. He previously served as Vice President and Chief Financial Officer of Global Groups at General Electric (GE) Transportation and Ecolab Healthcare & Life Sciences.

Dr. Angelo Acquista, Founder and Chief Medical Officer: A leading pulmonologist based in New York City, Dr. Acquista founded Peerbridge Health with the vision of creating patient-friendly cardiac monitoring solutions.

Leadership Changes

In 2023, Peerbridge Health appointed Chris Darland as President and CEO, succeeding Adrian Gilmore. Darland's extensive experience in global finance and operations is expected to drive the company's growth in remote healthcare.

Competitor Profile

Market Insights and Dynamics

The remote cardiac monitoring market is experiencing significant growth, driven by the increasing prevalence of cardiovascular diseases and the demand for non-invasive diagnostic tools. Advancements in wearable technology and AI have further propelled this market, offering opportunities for companies like Peerbridge Health to innovate and expand their offerings.

Competitor Analysis

Key competitors in the remote cardiac monitoring space include:

iRhythm Technologies: Known for its Zio patch, a single-lead ECG monitoring device that provides continuous cardiac monitoring.

BioTelemetry (a Philips company): Offers a range of cardiac monitoring services and devices, including mobile cardiac telemetry and Holter monitoring.

AliveCor: Develops personal ECG devices, such as KardiaMobile, which allow users to record ECGs using smartphones.

These companies focus on various aspects of cardiac monitoring, from wearable devices to comprehensive monitoring services, contributing to a competitive landscape in the industry.